Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration (ESCAPE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02194166
Recruitment Status : Completed
First Posted : July 18, 2014
Last Update Posted : October 29, 2018
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This multicenter study in participants with HER2-positive eBC will investigate participants' pain and discomfort of SC trastuzumab (Herceptin) administered either via a single-use injection device (SID) or via vial for manual administration using a hand-held syringe (SC vial). In total, participants will obtain at least 18 cycles/1 year of trastuzumab (4 cycles of intravenous [IV] and 14 cycles of SC trastuzumab).

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Trastuzumab Drug: Paclitaxel Drug: Docetaxel Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Randomized, Cross-Over, Multicenter, Phase IIIb Study, to Assess Patients' Tolerability of Trastuzumab Administrated Subcutaneously (SC) Either Via a Single Use Injection Device (SID) or Via Vial for Manual Administration (SC Vial) in Patients With HER2-Positive Early Breast Cancer (eBC)
Actual Study Start Date : July 18, 2014
Actual Primary Completion Date : July 12, 2018
Actual Study Completion Date : July 12, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Trastuzumab

Arm Intervention/treatment
Experimental: Pre-Randomization (Trastuzumab IV)
Trastuzumab IV will be given during the first 4 cycles for all participants before randomization for SC administration. A dose of 6 milligrams per kilogram (mg/kg) will be given every 3 weeks. All the participants will require a loading dose on Day 1 of Cycle 1, so they will receive 8 mg/kg followed by 6 mg/kg, 3 weeks later and then 3-weekly. Concurrent administration during the first 4 cycles of trastuzumab IV with paclitaxel/docetaxel will have to be performed in accordance with local hospital practice.
Drug: Trastuzumab
Trastuzumab IV or SC will be administered as described.
Other Name: Herceptin

Drug: Paclitaxel
Paclitaxel will be administered in accordance with local hospital practice.

Drug: Docetaxel
Docetaxel will be administered in accordance with local hospital practice.

Experimental: Group A: Trastuzumab SC (First Vial Formulation, then SID)
Participants will receive 7 cycles of SC trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation) followed by 7 cycles of SC trastuzumab 600 mg SID administration after cross-over.
Drug: Trastuzumab
Trastuzumab IV or SC will be administered as described.
Other Name: Herceptin

Experimental: Group B: Trastuzumab SC (First SID, then Vial Formulation)
Participants will start with 7 cycles of SC trastuzumab 600 mg administration via SID and after cross-over will receive 7 injections of trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation).
Drug: Trastuzumab
Trastuzumab IV or SC will be administered as described.
Other Name: Herceptin




Primary Outcome Measures :
  1. Participant Pain as Measured on a 10 Centimeter (cm) Visual Analogue Scale [ Time Frame: Week 13 up to Week 52 ]
  2. Participant Discomfort as Measured on a 10 cm Visual Analogue Scale [ Time Frame: Week 13 up to Week 52 ]

Secondary Outcome Measures :
  1. Healthcare Professional Satisfaction With SC Formulation as Assessed by Health Care Professional Questionnaire (HCPQ) [ Time Frame: Week 22 ]
  2. Patient Satisfaction With SC Formulation as Assessed by Patients Satisfaction Questionnaire (PSQ) [ Time Frame: Week 52 ]
  3. Healthcare Professional Perceived Time Savings With SC Trastuzumab as Assessed by HCPQ [ Time Frame: Week 22 ]
  4. Percentage of Participants With Adverse Events [ Time Frame: Baseline up to approximately 3 years ]
  5. Overall Survival [ Time Frame: From first study treatment to death from any cause, assessed up to approximately 4.5 years ]
  6. Disease-Free Survival, Assessed as per Institutional Practice or American Society of Clinical Oncology (ASCO) Adjuvant Follow-up Guidelines 2006 [ Time Frame: From first study treatment to documented disease progression or death, assessed up to approximately 3 years ]
  7. Number of Days on Trastuzumab Treatment [ Time Frame: Week 1 up to Week 52 ]
  8. Total Daily Dose of Trastuzumab [ Time Frame: Week 1 up to Week 52 ]
  9. Cumulative Dose of Trastuzumab [ Time Frame: Week 1 up to Week 52 ]
  10. Duration of Treatment [ Time Frame: Week 1 up to Week 52 ]
  11. Duration of Safety Observation [ Time Frame: 28 days after last study treatment (up to Week 56) ]
  12. Duration of Follow-Up [ Time Frame: 25 months after last study treatment (up to 3 years) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Hormonal therapy allowed as per institutional guidelines
  • Left ventricular ejection fraction (LVEF) of greater than or equal to (>/=) 55 percent (%) measured by echocardiography (ECHO) prior to first dose of trastuzumab
  • HER2-positive disease immunohistochemistry (IHC) 3+ or in-situ hybridization (ISH) positive as determined in a local laboratory that is experienced/certified in HER2-expression testing using an accurate and validated assay
  • Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast
  • No evidence of residual, locally recurrent or metastatic disease after completion of surgery and chemotherapy, or during concurrent chemotherapy (neo-adjuvant or adjuvant)
  • Participants who have completed all (neo)adjuvant treatment or participants after adjuvant chemotherapy with doxorubicin and cyclophosphamide (AC) to whom the 4 subsequent cycles of trastuzumab in combination with paclitaxel or docetaxel are indicated per local practice
  • Not more than 3 months should have elapsed since the last dose of adjuvant chemotherapy in case of subsequent treatment scheme

Exclusion Criteria:

  • Previous neoadjuvant or adjuvant breast cancer treatment with an approved or investigational anti-HER2 agent
  • History of other malignancy that can affect compliance with the protocol or interpretation of results. Participants with curatively treated carcinoma in situ of the cervix or basal cell carcinoma, and participants with other curatively treated malignancies who have been disease-free for at least 5 years, are eligible. Participants with previous ductal carcinoma in situ (DCIS) of the breast are also eligible for the study
  • Participants with severe dyspnea at rest or requiring supplementary oxygen therapy
  • Participants with other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness
  • Prior maximum cumulative dose of doxorubicin >360 mg/m2 or maximum cumulative dose of epirubicin >720 mg/m2 or equivalent
  • Serious cardiac illness or medical conditions that would preclude the use of trastuzumab, specifically: history of documented congestive heart failure (CHF), high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically significant valvular disease, evidence of transmural infarction on electrocardiogram (ECG), diagnosed poorly controlled hypertension
  • Known infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV)
  • Pregnant or lactating women
  • Concurrent enrollment in another clinical trial using an investigational anticancer treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment
  • Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of Herceptin®, or the adhesive of the SC device, or a history of severe allergic or immunological reactions, e.g., difficult to control asthma
  • Inadequate bone marrow, hepatic, or renal function
  • Major surgical procedure or significant traumatic injury within 14 days prior to the first dose of study treatment or anticipated need for major surgery during the course of study treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02194166


Locations
Layout table for location information
Belarus
State Inst N.N. Alexandrov Republican Scientific & Practical Centre of Oncology & Medical Radiology
A/g Lesnoy, Minsk Region, Belarus, 223040
Healthcare Institution "Brest Regional Oncologic Dispensary"
Brest, Belarus, 224027
Minsk City Clinical Oncologic Dispensary
Minsk, Belarus, BU-220013
Vitebsk Regional Clinical Oncology Dispensary
Vitebsk, Belarus, BU-210603
Kazakhstan
Kazakh Scientific Research Institution Of Oncology and Radiology; Chemotherapy department
Almaty, Kazakhstan, 050022
Almaty Cancer Hospital; Chemotherapy department
Almaty, Kazakhstan, 050060
Oncology centre of Astana; Chemotherapy department
Astana, Kazakhstan, 010000
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02194166     History of Changes
Other Study ID Numbers: ML28839
First Posted: July 18, 2014    Key Record Dates
Last Update Posted: October 29, 2018
Last Verified: October 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Docetaxel
Albumin-Bound Paclitaxel
Trastuzumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological